- Details
- Ashish Kamat interviews Shilpa Gupta about the best of ASCO 2024 in advanced bladder cancer. Dr. Gupta discusses three abstracts: the CheckMate-901 trial's analysis of complete responders to Nivolumab plus gemcitabine-cisplatin in lymph node-only metastatic urothelial cancer; patient-reported outcomes from the EV-302 trial comparing enfortumab vedotin plus pembrolizumab to platinum chemotherapy; a...
|
- Details
- Zach Klaassen interviews Roger Li about the CORE-001 trial for BCG-unresponsive non-muscle invasive bladder cancer. Dr. Li highlights the significant need for bladder-sparing therapies for patients who are too frail or unwilling to undergo radical cystectomy. The trial explores the combination of cretostimogene grenadenorepvec, an oncolytic immunotherapy, with pembrolizumab. This combination shows...
|
- Details
- Ashish Kamat hosts a discussion with Roger Li and Trinity Bivalacqua on the CORE-001 study evaluating cretostimogene grenadenorepvec and pembrolizumab for BCG-unresponsive CIS. Dr. Li highlights the 83% complete response rate at any time, 57.1% at 12 months, and 54.3% at 24 months, noting the therapy's durability and lack of progression to muscle-invasive or metastatic disease. The combination the...
|
- Details
- Mark Tyson presents results from the BOND-003 study, evaluating the efficacy of cretostimogene grenadenorepvec monotherapy in treating BCG-unresponsive non-muscle-invasive bladder cancer. Cretostimogene, an oncolytic adenovirus, selectively targets and destroys cancer cells while sparing normal tissue and boosting antitumor immunity. The phase III study reported a 75.2% complete response rate, wit...
|
- Details
- Sam Chang converses with Trinity Bivalacqua about treatments in non-muscle invasive bladder cancer, focusing on Cretostimogene grenadenorepvec (Creto), an oncolytic adenovirus, CG0070. Dr. Bivalacqua discusses trials exploring Creto's efficacy in managing BCG-unresponsive CIS, emphasizing its dual mechanism of action: direct tumor lysis and immune system activation. Initial results from the BOND-0...
|
- Details
- Ashish Kamat and Mark Tyson discuss the currently enrolling PIVOT-006 study. Dr. Tyson discusses cretostimogene grenadenorepvec, a conditionally replicating oncolytic adenovirus designed for cancer cell destruction and immunotherapeutic effects. Highlighting four pivotal studies demonstrating the agent's efficacy, especially in BCG unresponsive populations, Dr. Tyson outlines the development of in...
|
- Details
- Ashish Kamat welcomes Professor Mark Tyson to discuss the BOND-003 study results on CG0070, cretostimogene grenadenorepvec (creto), for BCG-unresponsive non-muscle invasive bladder cancer. Creto, an oncolytic adenovirus, selectively infects and kills cancer cells while sparing normal tissue and induces antitumor immunity. The phase 3 study showed a 75.7% complete response at any time point, with 7...
|
- Details
- Zach Klaassen and Rob Svatek explore the potential of cretostimogene, a novel medication for non-muscle invasive bladder cancer. Dr. Svatek describes cretostimogene as an oncolytic virus targeting cells with retinoblastoma pathway defects, common in cancer cells. This treatment, when instilled in the bladder, prompts immune cells to destroy cancer cells. Highlighted are several key trials: CORE-00...
|
